India Globalization Capital rebrands as IGC Pharma, effective March 30, 2023

IGC Pharma, Inc.

Name change to IGC Pharma, Inc. effective March 30, 2023; ticker symbol IGC unchanged.
Company highlights focus on THC-based drug IGC-AD1 in Phase 2 trials for Alzheimer's agitation.
IGC-AD1 is the only natural, THC-based investigational drug in FDA trials for Alzheimer's.
Wellness brand Holief targets premenstrual syndrome, menstrual cramps, and sleep disorders.
CEO Ram Mukunda states rebranding aligns name with strategic pharma focus.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

IGC Pharma, Inc.: Company changed name from India Globalization Capital Inc. to IGC Pharma, Inc. via Articles of Amendment to Amended and Restated Articles of Incorporation (effective 2023-03-30).

Change: charter amendment
Effective: 2023-03-30

Exact text from the filing

Effective March 30, 2023, India Globalization Capital Inc., a Maryland corporation (the “we,” “our,” “us” or the “Company”), changed its name to “IGC Pharma, Inc.” by filing Articles of Amendment to the Company’s Amended and Restated Articles of Incorporation with the State Department of Assessments and Taxation of Maryland on March 7, 2023 (the “Charter Amendment”).

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

IGC Pharma, Inc.: Amended Amended and Restated Bylaws solely to reflect the name change (effective 2023-03-07).

Change: bylaw amendment
Effective: 2023-03-07

Exact text from the filing

In addition, the Company adopted an Amendment to its Amended and Restated Bylaws, (the “Bylaw Amendment”), effective March 7, 2023, solely to reflect the name change.

View on SEC.gov

Browse all governance changes →

IGC Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001185185-23-000238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.